Patents by Inventor Allen A. Fienberg

Allen A. Fienberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20140050783
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 30, 2013
    Publication date: February 20, 2014
    Applicant: INTRA-CELLULAR THERAPIES INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • Methods and compositions for sleep disorders and other disorders
    Patent number: 8598119
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: December 3, 2013
    Assignee: Intra-Cellular Therapies, Inc.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20120053190
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
    Type: Application
    Filed: May 13, 2010
    Publication date: March 1, 2012
    Inventors: Allen A. Fienberg, Lawrence J. Wennogle, Sharon Mates
  • PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS
    Publication number: 20110312978
    Abstract: Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering agents. Topical and systemic therapy may be used.
    Type: Application
    Filed: February 24, 2010
    Publication date: December 22, 2011
    Inventors: Robert Davis, Allen Fienberg
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20110071080
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 24, 2011
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
  • NOVEL USES
    Publication number: 20100323997
    Abstract: The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.
    Type: Application
    Filed: December 5, 2007
    Publication date: December 23, 2010
    Applicant: INTRACELLULAR THERAPIES, INC.
    Inventors: Allen A. Fienberg, Sharon Mates, Lawrence P. Wennogle
  • ORGANIC COMPOUNDS
    Publication number: 20100087450
    Abstract: The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment and/or prophylaxis of narcolepsy.
    Type: Application
    Filed: November 13, 2007
    Publication date: April 8, 2010
    Applicant: Intra-Cellular Therapies, Inc.
    Inventors: Sharon Mates, Allen A. Fienberg
  • Method of treating psychosis and/or hyperactivity
    Patent number: 6013621
    Abstract: The present invention discloses the bidirectional regulation of DARPP-32 phosphorylation by dopamine and dopamine D1 and D2 receptors. This disclosure leads to new methodology in the treatment of schizophrenia and related disorders. In addition, the present invention provides methods for identifying agents that can be used in such treatment.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: January 11, 2000
    Assignee: The Rockfeller University
    Inventors: Akinori Nishi, Gretchen L. Snyder, Allen A. Fienberg, Paul Greengard
  • Knockout mutant mouse for DARPP-32 and use thereof
    Patent number: 5777195
    Abstract: A knockout mouse containing a non-functional allele for the gene that naturally encodes and expresses functional DARPP-32 is disclosed. This mouse contains two non-functional alleles for the gene that naturally encodes and expresses functional DARPP-32, and therefore is unable to express functional DARPP-32. This mouse finds utility as a screening model for potential therapeutic agents useful in the treatment of schizophrenia, Parkinson's disease, and the treatment of addictions, especially those involving drugs of abuse.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: July 7, 1998
    Assignee: The Rockefeller University
    Inventors: Allen A. Fienberg, Paul Greengard